Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)Christopher J Edwards, Paul Bird, Francisco J. Blanco et al.|Annals of the Rheumatic Diseases|2016Cited by 286
Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trialAlvin F. Wells, Jacob Aelion, Christopher J Edwards et al.|Lara D. Veeken|2018Cited by 101
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patientsAlvin F. Wells, Jacob Aelion, Nikolay Delev et al.|Lara D. Veeken|2021Cited by 12
THU0432 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled TrialsArthur Kavanaugh, P. J. Mease, Dafna D. Gladman et al.|Annals of the Rheumatic Diseases|2016Cited by 6
SAT0382 Palace 4, A Phase 3, Randomized, Controlled TRIAL of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-WEEK) Improvements in Physical FunctionA. Wells, Jacob Aelion, Christopher J Edwards et al.|Annals of the Rheumatic Diseases|2014Cited by 3